| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Niagen Bioscience, Inc. (NAGE) has 8 insiders with recent SEC Form 4 filings, including 7 buys and 5 sells. NAGE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 20.0K | $83.0K | - | |
| Dir | 20.0K | $83.0K | - | |
| Dir | 20.0K | $83.0K | - | |
| Dir | 20.0K | $83.0K | - | |
| Dir | 20.0K | $83.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 11, 2019 | Farr Kevin M69 | Chief Financial Officer | Buy | 5,700 | $3.49 | $19,893.00 | +57.0% | |
| Sep 11, 2018 | Farr Kevin M69 | Chief Financial Officer | Buy | 5,000 | $3.50 | $17,500.00 | +100.0% | |
| May 18, 2018 | Farr Kevin M69 | Chief Financial Officer | Buy | 5,000 | $3.83 | $19,150.00 | New | |
| May 17, 2018 | Friedman Mark J | General Counsel | Buy | 3,000 | $3.60 | $10,800.00 | New | |
| May 16, 2018 | Jaksch Frank L Jr | CEO | Buy | 9,800 | $3.59 | $35,163.00 | +2.4% | |
| Mar 29, 2018 | Jaksch Frank L Jr | CEO | Sale+OE | 474 | $4.60 | $2,180.40 | -0.2% | |
| Mar 27, 2018 | Jaksch Frank L Jr | CEO | Sale+OE | 24,578 | $4.60 | $113,058.80 | -10.9% | |
| Jan 11, 2018 | Jaksch Frank L Jr | CEO | Sale+OE | 28,379 | $6.52 | $184,906.10 | -6.6% | |
| Dec 21, 2017 | Jaksch Frank L Jr | CEO | Sale+OE | 58,400 | $6.19 | $361,496.00 | -22.5% | |
| Nov 17, 2017 | Champion River Ventures Ltd | 10% Owner | Buy | 731,707 | $4.10 | $2,999,998.70 | +12.7% |